Abstract Details

Title Efficacy of Gantenerumab Compared to Placebo in Adults with Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis of Cognitive Function and Amyloid Plaque Reduction

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P2 - Poster Session 2 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-008

Objective

This systematic review and meta-analysis assessed gantenerumab's impact on cognitive and functional outcomes, safety, and biomarker changes in individuals with Alzheimer’s Disease (AD).

Background Alzheimer’s Disease (AD) is thought to account for 60-70% of dementia cases globally. The progressive neurodegeneration unique to AD causes terrible cognitive decline, memory loss, and functional impairment. Gantenerumab, a fully human monoclonal antibody, has been explored as a disease-modifying therapy for AD.

Design/Methods

We conducted a comprehensive literature search of PubMed, Embase, and Cochrane databases from inception to May 25, 2025, for randomized controlled trials (RCTs) comparing gantenerumab to placebo in patients with AD. Review was registered with PROSPERO (CRD420251067883). Data on study characteristics, cognitive and functional efficacy outcomes, and severe adverse events (SAEs) were extracted. Pooled estimates were calculated using a random-effects model in RevMan (v5.4.1).

Results A total of seven randomized controlled trials (RCTs) encompassing 6,847 participants were included in this meta-analysis. Gantenerumab was associated with statistically significant improvements in cognitive outcomes. Specifically, there was a notable effect on Clinical Dementia Rating Sum of Boxes (CDR-SB) (SMD = -0.07; 95% [CI]: -0.12 to -0.02; p = 0.009; I² = 0%). Additionally, Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS Cog13) (SMD = -0.10; 95% CI: -0.15 to -0.04; p = 0.0006; I² = 0%), and Mini-Mental State Examination (MMSE) ( MD = -0.28; 95% CI: -0.52 to -0.05; p = 0.02; I² = 0%), all suggested gantenerumab over placebo. However, gantenerumab significantly increased the risk of amyloid-related imaging abnormalities, including ARIA-E risk ratio of 7.79 (95% CI: 4.29 to 14.15; p < 0.00001) and ARIA-H risk ratio of 2.25 (95% CI: 1.96 to 2.58; p < 0.00001).

Conclusions Gantenerumab demonstrates modest benefits in functional outcomes. Although, a substantial increase in ARIA incidence counterbalances these benefits. Further long-term trials are needed to determine optimal use benefits from gantenerumab therapy.

Authors/Disclosures
Jawaria Firdous PRESENTER	Dr. Firdous has nothing to disclose.
Laiba Khalid	Dr. Khalid has nothing to disclose.
Naila Zainab, MBBS	Dr. Zainab has nothing to disclose.
Muhammad Umar Ejaz, MBBS	Dr. Ejaz has nothing to disclose.
Areeba Tabassum, MBBS	Dr. Tabassum has nothing to disclose.
zaheer muhammad ahmed, Jr., MBBS	Dr. muhammad ahmed has nothing to disclose.
Tayyaba N. Abbasi, MBBS	Dr. Abbasi has nothing to disclose.
Iffah Zafar gondal, MBBS	Miss Zafar gondal has nothing to disclose.
Hamza Ashraf	Hamza Ashraf has nothing to disclose.
Umaimah Naeem	Dr. Naeem has nothing to disclose.
Muhammad Mohsin Khan, MBBS	Dr. Khan has nothing to disclose.
Atif N. Malik, MD	Dr. Malik has nothing to disclose.
Faseeh Haider, MD, MBBS	Dr. Haider has nothing to disclose.
Syed H. Inam, MD	Dr. Inam has nothing to disclose.

��ɫ��

��ɫ��